Skip to main content
. 2018 Aug 31;9(68):32958–32971. doi: 10.18632/oncotarget.26010

Figure 1. MAP17 upregulation in rectal tumors after concurrent chemoradiotherapy.

Figure 1

(A) Overall survival analysis of the rectal tumor cohort (Supplementary Table 1) used in this study. (B) Representative pictures of MAP17-stained rectal tumor samples. An ROC curve was used to identify the cut-off point (0.75). (C) Percentage of tumors positive and negative for MAP17 in our cohort of rectal tumor samples (n = 135). (D) MAP17 mRNA expression levels in non-tumor colon (n = 5) and rectal mucinous adenocarcinomas (n = 4). (E) MAP17 mRNA expression levels in samples from patients without metastasis (NO) vs patients with metastasis (YES).